Published on November 7, 2023, 12:59 am
For individuals who are struggling to lose weight, there is a glimmer of hope in the form of new weight loss drugs. The market is currently flooded with these medications, offering promises of various benefits. One medication that has been generating a lot of buzz recently is semaglutide, known by its brand name Wegovy or its Type 2 diabetes version called Ozempic. Dr. Fatima Cody Stanford, an expert in obesity medicine at Massachusetts General Hospital, attests to being frequently asked about this drug.
In terms of expectations, Dr. Stanford states that the average total body weight loss from using semaglutide is around 15%. This can potentially lead to improvements in health conditions such as diabetes and obstructive sleep apnea. These significant lifestyle changes offer a ray of hope for millions of Americans who are eligible to try these medications.
The Food and Drug Administration (FDA) has already approved six drugs for long-term weight loss. These drugs can be prescribed to individuals with a body mass index (BMI) of 30 or higher. Additionally, they are available to those with a BMI of 27 or higher who also have comorbidities such as diabetes or high blood pressure related to their weight.
Dr. Stanford highlights that nearly half of Americans could meet the criteria for anti-obesity medications. Even though Massachusetts has a lower percentage of people with obesity compared to other states, it still qualifies at least 1.5 million adults for these medications.
However, currently, the supply of Wegovy cannot keep up with the demand nationwide. This limitation poses challenges for doctors like Dr. Stanford who are unable to provide Wegovy immediately to their patients due to supply constraints.
Fortunately, there are alternative options available on the market such as Saxenda and Qsymia. Saxenda requires a daily injection while Qsymia comes in the form of a daily capsule. Although both medications offer slightly lower total body weight loss percentages (around 5% to 10%) compared to Wegovy, they may be more effective for certain individuals.
Dr. Stanford emphasizes that it is not a matter of using one drug over another, but rather a personalized approach to treatment. This often involves combination therapy where multiple medications are used to achieve the desired weight loss for each patient.
Novo Nordisk, the pharmaceutical company manufacturing Wegovy, predicts that shortages of the medication will persist until next year. To ensure an uninterrupted supply for existing patients, the company will restrict the number of starter doses available for new patients. However, Dr. Stanford reassures that there are other drugs in development that may prove even more effective.
Excitingly, some upcoming medications aim to deliver weight loss percentages as high as 20% to 25%, comparable to those achieved through metabolic and bariatric surgery. These innovative advancements signal a hopeful future in obesity medicine.
It is important to note that safety considerations must be taken into account when exploring new weight loss drugs. For instance, it is essential to assess their suitability for children before prescribing them.
In conclusion, the plethora of new weight loss drugs flooding the market offers hope and potential solutions for individuals struggling with weight management. While some medications like Wegovy may face supply constraints at present, alternatives such as Saxenda and Qsymia are available and can yield significant results for appropriate candidates. The field of obesity medicine is rapidly advancing, with upcoming drugs aiming to achieve even higher levels of weight loss. It is an exciting time for this specialization as novel medications continue to revolutionize the treatment landscape and provide viable options for those seeking long-term weight management solutions.
(Note: Please consult a healthcare professional before beginning any new medication or weight loss regimen.)